FMP

FMP

Enter

IKT - Inhibikase Therapeut...

Financial Summary of Inhibikase Therapeutics, Inc.(IKT), Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Pa

photo-url-https://financialmodelingprep.com/image-stock/IKT.png

Inhibikase Therapeutics, Inc.

IKT

NASDAQ

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

1.63 USD

0.05 (3.07%)

About

ceo

Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D.

sector

Healthcare

industry

Biotechnology

website

https://www.inhibikase.com

exchange

NASDAQ

Description

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in ...

CIK

0001750149

ISIN

US45719W2052

CUSIP

45719W106

Address

3350 Riverwood Parkway SE

Phone

678 392 3419

Country

US

Employee

8

IPO Date

Dec 23, 2020

Summary

CIK

0001750149

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

45719W106

ISIN

US45719W2052

Country

US

Price

1.63

Beta

1.2

Volume Avg.

131.96k

Market Cap

10.56M

Shares

-

52-Week

0.79-4.35

DCF

0.38

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.46

P/B

-

Website

https://www.inhibikase.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest IKT News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep